Welcome to our dedicated page for ARTIVA BIOTHERAPEUTICS SEC filings (Ticker: ARTV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Artiva Biotherapeutics filings document its clinical-stage biotechnology business, Nasdaq-listed common stock and material-event reporting. Recent Form 8-K disclosures cover quarterly and annual financial results, Regulation FD updates on AlloNK® (AB-101) clinical data, and exhibits such as press releases and corporate presentations.
The filing record also describes governance and compensation matters, including board and officer appointments, employment arrangements, non-employee director compensation, inducement awards and an option-for-RSU exchange under the 2024 Equity Incentive Plan. Artiva’s disclosures identify AlloNK as an off-the-shelf NK cell therapy candidate used with anti-CD20 monoclonal antibodies in autoimmune-disease trials, alongside standard public-company capital-structure and securities information.
Artiva Biotherapeutics, Inc. appointed Elaine Sorg as a Class I director, with her term running until the company’s 2028 annual meeting of stockholders. The Board acted on the recommendation of its Nominating and Corporate Governance Committee, and there are no related-party arrangements or transactions requiring disclosure.
Ms. Sorg brings more than 35 years of senior executive experience at major pharmaceutical companies, including roles as Senior Vice President and President of AbbVie’s U.S. commercial operations until her retirement in January 2024. She also serves on the board of CSL Limited, on Purdue University’s Dean’s Advisory Council, as a Senior Advisor at Boston Consulting Group, and on the Scientific Strategy Board of Galapagos.
Under Artiva’s Non-Employee Director Compensation Policy, she will receive an annual cash retainer of $40,000 and an initial option to purchase 27,500 shares of common stock, with one-third vesting shortly after grant and the remainder vesting monthly over two additional years, subject to continuous service. She is also eligible for automatic annual option grants to purchase 13,750 shares at each annual meeting, vesting over about one year, with all such options vesting in full upon a change in control, subject to the plan terms.
Artiva Biotherapeutics reported that SVP of Research and Development Heather Raymon received a grant of 46,000 shares of common stock in the form of restricted stock units under the company’s 2024 Equity Incentive Plan. On the same date, 1,521 shares at $4.00 per share were withheld to cover income tax obligations linked to restricted stock unit vesting, leaving Raymon with 151,323 directly owned shares.
Artiva Biotherapeutics, Inc. Chief Tech Operations Officer Christopher Horan reported equity compensation and a related tax withholding transaction in company stock. He received a grant of 117,300 shares of common stock as a restricted stock unit award under the company’s 2024 Equity Incentive Plan. On the same date, 2,187 shares of common stock at a price of $4.00 per share were withheld by the company to cover income tax obligations arising from the vesting of restricted stock unit awards. After these transactions, Horan directly owned 300,452 shares of Artiva’s common stock.
Artiva Biotherapeutics COO and CLO Jennifer Bush reported equity compensation and related tax withholding transactions in company stock. She received a grant of 117,300 shares of common stock as a restricted stock unit award under Artiva’s 2024 Equity Incentive Plan. On the same date, 3,515 shares were withheld by Artiva at a price of $4.00 per share to cover income tax obligations tied to vesting of restricted stock units, rather than sold in the open market. After these transactions, she directly owned 346,710 shares of Artiva common stock.
Artiva Biotherapeutics, Inc. reported that its Chief Medical Officer, Subhashis Banerjee, acquired 102,000 shares of common stock through a grant described as a restricted stock unit award under the company’s 2024 Equity Incentive Plan. Following this equity award, his directly held common stock ownership increased to 152,000 shares.
Artiva Biotherapeutics reported insider equity activity by President and CEO Fred Aslan. He acquired 366,850 shares of common stock through a restricted stock unit award granted under the company’s 2024 Equity Incentive Plan, and 14,600 shares were withheld at $4.00 per share to cover income tax obligations from vesting. Following these transactions, he directly owned 1,562,198 common shares.
Artiva Biotherapeutics, Inc. reported an insider stock sale by its president and CEO, who also serves as a director. On December 15, 2025, the insider sold 3,187 shares of common stock at $6 per share.
Following this transaction, the insider directly owned 1,209,948 shares of Artiva Biotherapeutics common stock. The filing notes that the sale occurred under a Rule 10b5-1 trading plan adopted by the reporting person on July 23, 2024.
Artiva Biotherapeutics, Inc. reported an insider equity transaction for its SVP, Research and Development. On December 12, 2025, the officer received 67,253 restricted stock units (RSUs) of common stock at a price of $0, bringing their directly held common shares to 106,844.
On the same date, the company cancelled several employee stock options held by the officer pursuant to an option exchange, with exercise prices ranging from $5.01 to $13.47, leaving 0 derivative securities beneficially owned. The cancelled options had been scheduled to vest over multi-year periods based on continued service.
Artiva Biotherapeutics granted its Chief Tech Operations Officer 107,156 restricted stock units (RSUs) of common stock on December 12, 2025 under its 2024 Equity Incentive Plan as part of an option exchange.
On the same date, the company cancelled employee stock options covering 77,519 and 9,119 shares at an exercise price of $5.01 and options for 20,519 shares at $13.47, in exchange for the new RSUs. After these transactions, the officer directly beneficially owns 185,339 shares of Artiva common stock.
Artiva Biotherapeutics, Inc. reported that a senior officer (COO, CLO, Secretary and Compliance Officer) exchanged stock options for restricted stock units on December 12, 2025.
The officer received 84,877 restricted stock units granted under the company’s 2024 Equity Incentive Plan at a stated price of $0, bringing direct beneficial ownership to 232,925 shares of common stock.
As part of the same option exchange, the company cancelled employee stock options to buy 41,039, 9,119, 14,202 and 20,519 shares of common stock with exercise prices ranging from $5.01 to $13.47, all of which now show zero derivative securities beneficially owned.